Comparison of Two Types of Radiofrequency Treatment for Trigeminal Neuralgia

Launched by MESUT BAKIR · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different methods of radiofrequency treatment for a painful condition called trigeminal neuralgia, which causes sharp pain in the face. When medications don’t work anymore, doctors may use a procedure called radiofrequency ablation (RFA) to help relieve pain. This study compares two types of RFA: one that uses heat on a specific nerve area and another that uses a pulsed technique on the nerve branches. The goal is to see which method provides better pain relief, patient satisfaction, and fewer complications.

To be eligible for this trial, participants should be between 55 and 80 years old and have been diagnosed with classical trigeminal neuralgia that hasn't responded to treatments for at least six months. The study will review patient records and follow up on their progress for six months after the procedure. It's important to note that people with certain conditions or previous facial surgeries won't be included. This research aims to help doctors choose safer and more effective treatments to improve the quality of life for patients suffering from this painful condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged between 55 and 80 years with a diagnosis of classical trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd edition (ICHD-3). Patients must have experienced pain refractory to medical management for at least 6 months and have complete clinical and procedural records available, including follow-up data for a minimum of 6 months.
• Exclusion Criteria:
• • Patients with secondary trigeminal neuralgia due to structural causes such as multiple sclerosis or tumors, those with a history of prior craniofacial surgery or neuroablative procedures, patients lacking sufficient follow-up data, and those with contraindications to sedation or with uncontrolled systemic comorbidities are excluded from the study.